Results 111 to 120 of about 7,977 (217)

Body fat in nonobese women with prolactinoma treated with dopamine agonists

, 2007
OBJECTIVES: To evaluate body fat in nonobese women with prolactinoma treated with dopamine agonists, using whole body dual energy X-ray absorptiometry (DXA) and to correlate DXA results with biochemical data and clinical aspects of the prolactinoma ...
A. Lamounier Filho, E. C. Naliato, COLAO, ANNAMARIA, Y. Schrank, D. Caldas, C. R. Loureiro, P. L. Costa, A. H. Violante, R. Fontes, R. G. Souza   +9 more
core  

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance

Acta Neuropathologica Communications
Prolactinoma is the most prevalent pituitary neuroendocrine tumor and dopamine agonists (DAs) targeting dopamine D2 receptor (DRD2) are recommended as the first-line treatment. However, varying degrees of DA resistance limit patient benefit.
Yuyang Peng, Huachun Yin, Xiangdong Pei, Yuan Zhang, Chengcheng Wang, Xin Zheng, Hong Liang, Hui Yang, Song Li   +8 more
doaj   +1 more source

Modern approach to bone comorbidity in prolactinoma

Prolactinomas account for more than half of pituitary adenomas, and besides their clinical impact on fertility and gonadal function, they lead to detrimental effects on bone.
Menotti, Sara, Uygur, Meliha Melin, Giustina, Andrea, Santoro, Simona   +3 more
core   +1 more source

Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice. [PDF]

Pituitary
De Sousa SMC, Marcus HJ, Ovenden CD, Prevedello D, Petersenn S.   +4 more
europepmc   +1 more source

Evaluation of Diastolic Dysfunction in Pituitary Adenomas: A Comparative Single-Center Study Among Acromegaly, Prolactinoma, and Nonfunctioning Pituitary Adenomas. [PDF]

Medicina (Kaunas)
Eker Akıllı R, Altuntaş SÇ, Tepe O, Akray A, Zubaroglu ÜPA, İltaş A, Erdem T, Akbal E, Çağlayan EÇ.   +8 more
europepmc   +1 more source

Beyond tumor control: skeletal morbidity in giant prolactinoma. [PDF]

Endocr J
Dandinoğlu T.
europepmc   +1 more source

Importance of clinical profiling to determine excess mortality in prolactinomas: insights from a large, registry-based cohort. [PDF]

Pituitary
Shwaish TZT, Gori D, Sartori C, Guaraldi F.   +3 more
europepmc   +1 more source

Prolactinoma

Prolactinomas are benign pituitary tumors characterized by excessive secretion of prolactin. While more common in females, these tumors can also significantly impact male patients, leading to symptoms such as hypogonadism, infertility and gynecomastia.
Yatavelli RKR, Kaur J, Bhusal K.
europepmc   +2 more sources

Skeletal assessment in giant prolactinoma: a reply. [PDF]

Endocr J
Unver Ozkahraman A, Hatipoglu E.
europepmc   +1 more source

Endocrine and surgical outcomes after medial cavernous sinus wall resection for functioning pituitary adenomas: a systematic review and meta-analysis. [PDF]

Neurosurg Rev
Vargas LO, Himic V, Kazimli V, Cummings A, Kreatsoulas D, Jahangiri A, Aaronson DM, Shah AH, Komotar RJ, Ivan ME, Gersey ZC.   +10 more
europepmc   +1 more source